Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 153 | Publisher: Global Markets Direct
Industry: Oncology | Report Format: Electronic (PDF)

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015', provides an overview of the Peripheral T-Cell Lymphomas (PTCL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

 Table of Contents
Table of Contents 2
List of table 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral T-Cell Lymphomas (PTCL) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 9
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis 10
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 18
AB Science 18
Affimed Therapeutics AG 19
Bayer AG 20
Celgene Corporation 21
Eisai Co., Ltd. 22
Incyte Corporation 23
Karyopharm Therapeutics, Inc. 24
Kyowa Hakko Kirin Co., Ltd. 25
Millennium Pharmaceuticals, Inc. 26
Mundipharma International Limited 27
Onxeo SA 28
Sanofi 29
Solasia Pharma K.K. 30
Spectrum Pharmaceuticals, Inc. 31
TG Therapeutics, Inc. 32
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
AFM-13 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alemtuzumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
alisertib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
belinostat - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
copanlisib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
darinaparsin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
denileukin diftitox - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
forodesine hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
lenalidomide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
masitinib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
mogamulizumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pralatrexate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
romidepsin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ruxolitinib phosphate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
selinexor - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SH-7129 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TGR-1202 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 90
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 142
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 143
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 144
Featured News & Press Releases 144
Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 144
Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 144
Nov 13, 2014: Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq 145
Nov 06, 2014: Celgene To Present Phase II Trial Data On Romidepsin at American Society of Hematology Annual Meeting 146
Sep 16, 2014: Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq (belinostat) for Injection with Patent Term Adjustment till 2027 146
Aug 28, 2014: Onxeo Strengthens Beleodaq Patent Protection in the U.S. Until 2027 147
Jul 07, 2014: FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq (belinostat) for Injection 147
Jul 03, 2014: BioAlliance Pharma Receives FDA approval for Beleodaq 149
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 149
Feb 06, 2014: FDA Grants Acceptance To File And Priority Review For TopoTarget A/S's Beleodaq NDA In PTCL 149
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 152
Disclaimer 153

List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2015 9
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science, H1 2015 18
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2015 19
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2015 20
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2015 21
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2015 22
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2015 23
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 24
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 25
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 26
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Limited, H1 2015 27
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2015 28
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Sanofi, H1 2015 29
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2015 30
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 31
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 35
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2015 90
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2015 142
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2015 143